Applied BioMath's mission is to revolutionize drug invention. Applied BioMath applies biosimulation, including quantitative systems pharmacology, PKPD, bioinformatics, machine learning, clinical pharmacology, and software solutions to provide quantitative and predictive guidance to biotechnology and pharmaceutical companies to help accelerate and de-risk therapeutic research and development.
Our approach employs proprietary algorithms and software to support groups worldwide in decision-making from early research through all phases of clinical trials. We leverage our decades of expertise to help groups better understand their therapeutic, its best-in-class parameters, competitive advantages, patients, and the best path forward into and in the clinic to increase likelihood of clinical concept and proof of mechanism, and decrease late stage attrition rates.
Our Vision & Mission
Empowering scientists to invent transformative medicines by providing modeling and software that informs every decision.
Our mission is to develop the engineering, science, and software that revolutionizes drug invention. We partner with industry leaders and regulators to rapidly evaluate therapeutic concepts and increase clinical success. This will result in medicines that are safer, more effective, less expensive, and get to market faster.
Applied BioMath was awarded a grant for the development of a software platform called Antibody Drug Conjugate (ADC) Workbench to facilitate efficient knowledge discovery and enable rapid knowledge qualification in support of the development of Quantitative Systems Pharmacology Models (QSPM) for ADC projects.
Applied BioMath was awarded a grant for development of a quantitative systems pharmacology model of amyloid beta and tau pathways for clinical trial design and decision making in Alzheimer's Disease and Dementia.
Applied BioMath was awarded $1.5M by the National Institutes of Health (NIH) to enhance the company's proprietary tools and algorithms for analyzing nonclinical data and mechanisms and predicting clinical PK/PD for biologics.
We challenge the status quo. We are leaders who are empowered to take risks and push boundaries. We nurture curious, adventurous, and creative thinking. We seek opportunities for continuous improvement.
We value kindness and care about our people. We observe and listen, elevate and encourage each other, and always assume positive intent. We promote work/life balance and diversity.
We are adaptable. We strive to be prepared for any situation. We approach our challenges nimbly and with resilience.
Integrity, we do the right thing. We strive to honor our commitments, own up to, and learn from our mistakes. It is our responsibility to speak-up. We are accountable. We are ethical.
We build trust with transparency. We prioritize teamwork and strive to be an extension of our clients’ teams.
Excellence is a habit. We are results driven and passionate, with a steady drive towards quality. We consistently demonstrate a commitment to our goals.
Charitable Giving Program
At Applied BioMath, we believe strongly in giving back to our community. One of our founding principles is to try and make the world a better place. Our products and services help our commercial partners make a better world through development of novel medicines, but our efforts shouldn’t stop there. Embedded in our corporate DNA is the commitment to help others less fortunate than ourselves. As a part of our Corporate Mission, Applied BioMath will partake in an annual Charitable Giving Program, donating a portion of our profits to charities selected by our team. These may be national, international, or local endeavors; the only requirement is that their focus is on helping people.
Applied BioMath was founded in 2013 by Dr. John Burke, Dr. Joshua Apgar, and Andrew Sutherland to help revolutionize both the quality and economics of drug invention by applying MID3. Dr. Burke and Dr. Apgar have been leaders in the biological engineering field for decades beginning with their research at Arizona State University, MIT, and Harvard Medical School and continuing with their many roles in top pharmaceutical and biotechnology companies. They, along with Andrew Sutherland, built an innovative, experienced, and passionate team of mathematicians, biologists, engineers, clinical pharmacologists and pharmaceutical industry experts who leverage biology, proprietary technology, high-performance computing (HPC), and decades of industry experience.